Delcath Systems, Inc. - Common Stock (NQ:DCTH)

8.725 -0.275 (-3.06%)

Streaming Delayed Price Updated: 10:10 AM EST, Feb 27, 2026 Add to My Watchlist

Price and Volume

Volume	104,649
Open	9.010
Bid (Size)	8.690 (800)
Ask (Size)	8.760 (100)
Prev. Close	9.000
Today's Range	8.600 - 9.109
52wk Range	8.120 - 18.23
Shares Outstanding	7,906,728
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Delcath (DCTH) Q4 2025 Earnings Call Transcript ↗

February 26, 2026

Delcath (DCTH) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Delcath Systems Inc (NASDAQ:DCTH) Posts Q4 Beat, Provides Cautious 2026 Outlook ↗

February 26, 2026

Via Chartmill

Performance

YTD	-12.3%	-12.3%
1 Month	-14.5%	-14.5%
3 Month	-10.1%	-10.1%
6 Month	-19.8%	-19.8%
1 Year	-40.5%	-40.5%

More News

Delcath Systems Reports Fourth Quarter and Full Year 2025 Results

February 26, 2026

From Delcath Systems, Inc.

Via Business Wire

Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call

February 12, 2026

From Delcath Systems, Inc.

Via Business Wire

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

January 27, 2026

From Delcath Systems, Inc.

Via Business Wire

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 21, 2026

From Delcath Systems, Inc.

Via Business Wire

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

January 09, 2026

From Delcath Systems, Inc.

Via Business Wire

Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma

December 31, 2025

From Delcath Systems, Inc.

Via Business Wire

Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

December 03, 2025

From Delcath Systems, Inc.

Via Business Wire

Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program

November 20, 2025

From Delcath Systems, Inc.

Via Business Wire

Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma

November 18, 2025

From Delcath Systems, Inc.

Via Business Wire

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 14, 2025

From Delcath Systems, Inc.

Via Business Wire

Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients

November 13, 2025

From Delcath Systems, Inc.

Via Business Wire

Delcath Systems to Participate in Upcoming Investor Conferences

November 06, 2025

From Delcath Systems, Inc.

Via Business Wire

Delcath Systems Inc (NASDAQ:DCTH) Reports Q3 2025 Revenue Miss, Meets EPS Estimates ↗

November 04, 2025

Via Chartmill

Delcath Systems Reports Third Quarter 2025 Results and Business Highlights

November 04, 2025

From Delcath Systems, Inc.

Via Business Wire

Delcath Systems to Host Third Quarter 2025 Earnings Call

October 21, 2025

From Delcath Systems, Inc.

Via Business Wire

Why Delcath Systems Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket ↗

October 20, 2025

Via Benzinga

Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results

October 18, 2025

From Delcath Systems, Inc.

Via Business Wire

Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint

October 18, 2025

From Delcath Systems, Inc.

Via Business Wire

Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress

September 22, 2025

From Delcath Systems, Inc.

Via Business Wire

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 05, 2025

From Delcath Systems, Inc.

Via Business Wire

Delcath Systems to Participate in Upcoming Investor Conferences

August 21, 2025

From Delcath Systems, Inc.

Via Business Wire

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

August 19, 2025

From Delcath Systems, Inc.

Via Business Wire

Frequently Asked Questions

Is Delcath Systems, Inc. - Common Stock publicly traded?

Yes, Delcath Systems, Inc. - Common Stock is publicly traded.

What exchange does Delcath Systems, Inc. - Common Stock trade on?

Delcath Systems, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Delcath Systems, Inc. - Common Stock?

The ticker symbol for Delcath Systems, Inc. - Common Stock is DCTH on the Nasdaq Stock Market

What is the current price of Delcath Systems, Inc. - Common Stock?

The current price of Delcath Systems, Inc. - Common Stock is 8.725

When was Delcath Systems, Inc. - Common Stock last traded?

The last trade of Delcath Systems, Inc. - Common Stock was at 02/27/26 10:10 AM ET

What is the market capitalization of Delcath Systems, Inc. - Common Stock?

The market capitalization of Delcath Systems, Inc. - Common Stock is 68.99M

How many shares of Delcath Systems, Inc. - Common Stock are outstanding?

Delcath Systems, Inc. - Common Stock has 69M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.